100763
论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
小细胞肺癌 (SCLC) 抗血管生成治疗的进展
Authors Lu H, Jiang Z
Received 13 August 2016
Accepted for publication 8 December 2016
Published 12 January 2017 Volume 2017:10 Pages 353—359
DOI http://doi.org/10.2147/OTT.S119714
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ashok Kumar Pandurangan
Peer reviewer comments 4
Editor who approved publication: Dr Yao Dai
Abstract: Small-cell lung
cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid
growth rate, strong aggressiveness, early metastases, and poor prognosis.
Angiogenesis greatly contributes to the metastatic process of SCLC, which has a
higher vascularization compared with non-small-cell lung cancer (NSCLC). SCLC
might constitute an ideal malignancy for assessing new antiangiogenic drugs and
therapeutic strategies. Combining bevacizumab with paclitaxel has therapeutic
benefits in chemoresistant, relapsed SCLC. The cisplatin–etoposide and
bevacizumab combination, as the first-line treatment for extensive-stage SCLC,
can improve progression-free survival (PFS), with an acceptable toxicity
profile. Ziv-aflibercept combined with topotecan is promising for
platinum-refractory SCLC. Chemotherapy combined with thalidomide cannot prolong
survival. Maintenance sunitinib of 37.5 mg/day in extensive-stage SCLC patients
following induction chemotherapy with platinum/etoposide improves median PFS by
1.6 months. Serum angiopoietin-2 concentrations and vascular endothelial growth
factor levels correlate with poor prognosis. Bevacizumab, ziv-aflibercept, and
sunitinib are worthy of further evaluation. Thalidomide, sorafenib,
pomalidomide, and cediranib may not be suitable for SCLC.
Keywords: small-cell lung cancer, bevacizumab, sunitinib antiangiogenic therapy
Keywords: small-cell lung cancer, bevacizumab, sunitinib antiangiogenic therapy
Download Article[PDF]
